Commerzbank Aktiengesellschaft FI Buys 20,825 Shares of Abbott Laboratories $ABT

Commerzbank Aktiengesellschaft FI raised its stake in shares of Abbott Laboratories (NYSE:ABT) by 9.3% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 245,168 shares of the healthcare product maker’s stock after buying an additional 20,825 shares during the quarter. Commerzbank Aktiengesellschaft FI’s holdings in Abbott Laboratories were worth $32,838,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Norges Bank purchased a new stake in Abbott Laboratories during the 2nd quarter valued at about $3,026,180,000. Laurel Wealth Advisors LLC lifted its stake in shares of Abbott Laboratories by 13,347.0% in the second quarter. Laurel Wealth Advisors LLC now owns 6,056,934 shares of the healthcare product maker’s stock worth $823,804,000 after buying an additional 6,011,891 shares in the last quarter. Vanguard Group Inc. lifted its stake in shares of Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock worth $23,502,644,000 after buying an additional 2,977,715 shares in the last quarter. First Trust Advisors LP increased its position in shares of Abbott Laboratories by 180.7% during the second quarter. First Trust Advisors LP now owns 3,063,443 shares of the healthcare product maker’s stock valued at $416,659,000 after acquiring an additional 1,972,097 shares in the last quarter. Finally, TD Asset Management Inc increased its position in shares of Abbott Laboratories by 98.6% during the second quarter. TD Asset Management Inc now owns 3,467,896 shares of the healthcare product maker’s stock valued at $471,669,000 after acquiring an additional 1,721,523 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on ABT shares. Jefferies Financial Group increased their target price on Abbott Laboratories from $145.00 to $149.00 and gave the company a “buy” rating in a research note on Thursday, October 16th. The Goldman Sachs Group dropped their price objective on Abbott Laboratories from $152.00 to $140.00 and set a “buy” rating on the stock in a research report on Friday. Evercore ISI decreased their target price on Abbott Laboratories from $144.00 to $138.00 and set an “outperform” rating for the company in a research report on Friday. Piper Sandler dropped their price target on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a report on Friday. Finally, Weiss Ratings reiterated a “buy (b-)” rating on shares of Abbott Laboratories in a research note on Monday, December 29th. Two analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and three have issued a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $140.79.

Key Abbott Laboratories News

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: MedTech and pharma strength, and EPS resilience — Abbott reported adjusted Q4 EPS growth (company highlighted margin improvements) and strong MedTech (+~12%) and Established Pharma (+~9%) performance that partly offset Nutrition weakness; management still projects FY‑2026 adjusted EPS growth. Press Release
• Positive Sentiment: Analysts keep buy/outperform stance despite cuts — several major firms trimmed price targets after the print but largely maintained buy/overweight ratings, signaling conviction in the longer‑term story even as near‑term expectations were tempered. Analyst Reaction
• Positive Sentiment: Some commentators view the pullback as a buying opportunity — market commentators highlight ABT’s dividend history, cash flow and buyback capacity, suggesting the drop may create an attractive entry for long‑term investors. MarketBeat: Pullback Analysis
• Neutral Sentiment: Full earnings call and transcripts available — investors can review management commentary and segment detail in the Q4 earnings call transcript for color on nutrition, diagnostics and Exact/other strategic items. Earnings Transcript
• Neutral Sentiment: Dividend/valuation commentary circulates — value and dividend‑focused outlets are flagging ABT as attractively valued after the pullback; this is background context rather than a near‑term catalyst. Zacks: Value Take
• Negative Sentiment: Revenue miss driven by Nutrition and Diagnostics — Q4 revenue (~$11.5B) fell short of consensus, with Nutrition down sharply (~8–9%) and Diagnostics weak, sparking the initial selloff. Reuters: Revenue Miss
• Negative Sentiment: Guidance slightly below Street — Abbott set Q1 EPS and FY‑2026 EPS ranges that sit near or a touch below consensus, increasing near‑term revenue/growth concerns. Guidance Details
• Negative Sentiment: Multiple price‑target cuts — a raft of firms (Citigroup, Goldman, Raymond James, Sanford Bernstein, Oppenheimer, RBC, etc.) trimmed targets, which can amplify selling pressure even if ratings remain constructive. Benzinga: PT Cuts
• Negative Sentiment: Options and hedging activity spiked — an unusual surge in put buying suggests traders are positioning for further near‑term downside (heightened bearish sentiment).
• Negative Sentiment: Regulatory scrutiny in India — reports of an investigation into alleged misuse of a codeine‑based cough syrup (Abbott Healthcare) add an extra headline risk in emerging markets. Reuters: India Scrutiny

Abbott Laboratories Price Performance

Shares of NYSE:ABT opened at $107.46 on Friday. The firm’s 50 day moving average price is $124.77 and its 200-day moving average price is $128.33. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The stock has a market capitalization of $186.86 billion, a PE ratio of 28.89, a price-to-earnings-growth ratio of 1.78 and a beta of 0.72. Abbott Laboratories has a twelve month low of $105.78 and a twelve month high of $141.23.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share for the quarter, hitting the consensus estimate of $1.50. The business had revenue of $11.46 billion for the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The company’s quarterly revenue was up 4.4% on a year-over-year basis. During the same period last year, the firm earned $1.34 earnings per share. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Equities research analysts expect that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be paid a dividend of $0.63 per share. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date is Thursday, January 15th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is presently 67.74%.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.